Kaposi Sarcoma Clinical Trial
Official title:
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
sEphB4-HSA will be given through an intravenous infusion (into a vein). Each cycle of sEphB4-HSA will be 28 days (4 weeks). Each cycle of the study drug includes administration of 2 doses of sEphB4-HSA given on Days 1 and 15 of each cycle. Participants may continue on study protocol as long as their KS is continuing to respond or is clinically stable on study medication. Patients may come off treatment for the following reasons: - Disease progression. - Need for more than 2 dose reductions for toxicity. - Dose delay more than 28 days. - Patient withdraws consent. - Study termination by the Sponsor. - Participants who are noncompliant with respect to taking drugs, keeping appointments, or having tests required for the evaluation of drug safety and efficacy. - Participant's condition renders them unacceptable for further treatment in the judgment of the investigator. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06445166 -
Propranolol for the Treatment of Kaposi Sarcoma in Adults
|
Phase 2 | |
| Recruiting |
NCT04941274 -
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03160183 -
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
|
||
| Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
| Completed |
NCT00395278 -
Development of Serologic Assays for Human Herpes Virus-8
|
||
| Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT03296553 -
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
|
Phase 2 | |
| Recruiting |
NCT04305691 -
Trial of Ixazomib for Kaposi Sarcoma
|
Phase 2 | |
| Completed |
NCT03316274 -
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
|
Early Phase 1 | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Terminated |
NCT04893018 -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
|
Phase 1 | |
| Recruiting |
NCT06375122 -
Natural History Study of Kaposi Sarcoma
|
||
| Recruiting |
NCT05663502 -
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
|
||
| Recruiting |
NCT05329792 -
L19IL2/L19TNF in Skin Cancer Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05411237 -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
|
Phase 3 | |
| Completed |
NCT03050788 -
Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma
|
N/A | |
| Completed |
NCT03404297 -
Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya
|
N/A | |
| Terminated |
NCT01412515 -
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06004011 -
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
|
N/A | |
| Terminated |
NCT02080416 -
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
|
Phase 0 |